James D. Peyton

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma

John D. Hainsworth, Jeffrey R. Infante, David R. Spigel et al. · Cancer · 2010 · 76 citations

Pharmacy, Oncology, Pharmacotherapy +17

Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck

John D. Hainsworth, David R. Spigel, F. Anthony Greco et al. · The Cancer Journal · 2011 · 66 citations

Medicine, Oncology, Radiation Oncology +15

A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer.

Johanna C. Bendell, Anthony A. Meluch, James D. Peyton et al. · PubMed · 2012 · 56 citations

Medicine, Oncology, Radiation Oncology +17

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

Andrew H. Ko, Patrick Murphy, James D. Peyton et al. · The Oncologist · 2017 · 49 citations · Full text

Medicine, Oncology, Pharmacology +16

A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.

James D. Peyton, H. Burris, Carolyn D. Britten et al. · Journal of Clinical Oncology · 2011 · 46 citations

Pharmacy, Oncology, Pharmacology +17